Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric ulcerative colitis phase 3 study of subcutaneous golimumab versus infliximab
NL-OMON52852Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in autoimmune colitis comparing Golimumab arm with Infliximab arm (2 arms). Primary endpoints: Clinical remission by Mayo score and Safety profile. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
golimumabinfliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON52852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52852.